Detalhe da pesquisa
1.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Lancet Oncol
; 25(2): 175-183, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38218192
2.
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Eur J Nucl Med Mol Imaging
; 47(4): 895-906, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31838581
3.
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Eur J Nucl Med Mol Imaging
; 45(7): 1155-1169, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29484451
4.
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases.
Neuroendocrinology
; 106(1): 74-88, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-28728155
5.
Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
Eur J Nucl Med Mol Imaging
; 42(8): 1223-30, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25822655
6.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
J Nucl Med
; 63(3): 415-423, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34168013
7.
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.
Nucl Med Mol Imaging
; 55(3): 136-140, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34093893
8.
First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.
J Nucl Med
; 62(10): 1391-1397, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33547209
9.
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Clin Nucl Med
; 45(3): e165-e168, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31977464
10.
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Clin Nucl Med
; 45(1): e48-e50, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31162261
11.
Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy.
Clin Nucl Med
; 45(4): e198-e200, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31876836
12.
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
J Nucl Med
; 61(11): 1560-1569, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32169914
13.
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.
Clin Nucl Med
; 44(6): 501-503, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30932981
14.
Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial.
Clin Nucl Med
; 44(3): 223-226, 2019 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-30672759
15.
Metastatic Nasopharyngeal Carcinoma Treated With Intraarterial Combined With Intravenous Peptide Receptor Radionuclide Therapy.
Clin Nucl Med
; 44(12): 989-990, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31663867
16.
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
J Nucl Med
; 60(3): 377-385, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30115686
17.
177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
J Nucl Med
; 60(11): 1579-1586, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30850499
18.
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.
J Nucl Med
; 60(7): 955-962, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-30683770
19.
From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
Semin Nucl Med
; 49(5): 422-437, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31470935
20.
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
Oncotarget
; 10(25): 2451-2461, 2019 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31069008